Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California

Ritu Banerjee, Jennifer Allen, S. Y Grace Lin, Janice Westenhouse, Ed Desmond, Gisela F. Schecter, Cheryl Scott, Ann Raftery, Sundari Mase, James P. Watt, Jennifer Flood

Research output: Contribution to journalArticlepeer-review

Abstract

To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR TB.

Original languageEnglish (US)
Pages (from-to)3779-3781
Number of pages3
JournalJournal of Clinical Microbiology
Volume48
Issue number10
DOIs
StatePublished - Oct 2010
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California'. Together they form a unique fingerprint.

Cite this